StreetInsider.com News Articles

Form 144 Disc Medicine, Inc. Filed by: Yu Jonathan Yen-Wen

Tue, 16 Jun 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260616/26654723.html

Form 144 Disc Medicine, Inc. Filed by: Yu Jonathan Yen-Wen

Tue, 16 Jun 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260616/26654723.html

Disc Medicine (IRON) PT Raised to $85 at Morgan Stanley

Tue, 16 Jun 2026 08:39:06 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Disc Medicine (NASDAQ: IRON) to $85.00 (from $80.00) while maintaining a Overweight rating.

Disc Medicine reports positive clinical trial results at EHA meeting

Fri, 12 Jun 2026 08:31:12 -0400

Disc Medicine Inc. (NASDAQ: IRON) presented updated clinical trial data at the 2026 European Hematology Association Annual Meeting in Stockholm, Sweden.

The company reported results from its RALLY-MF Phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia. The trial enrolled 61 adult patients, with 50 patients included in the responder analysis. Among non-transfusion dependent patients, 55% achieved a hemoglobin increase of at least 1.5 g/dL for 12 weeks or longer. For transfusion-dependent patients with low transfusion burden, 64% achieved transfusion independence over a 16-week period. Among patients with high transfusion burden, 50% achieved transfusion independence over a 12-week period.

The

Disc Medicine reports positive clinical trial results at EHA meeting

Fri, 12 Jun 2026 08:31:12 -0400

Disc Medicine Inc. (NASDAQ: IRON) presented updated clinical trial data at the 2026 European Hematology Association Annual Meeting in Stockholm, Sweden.

The

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Fri, 12 Jun 2026 08:30:00 -0400

Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor use
Updated data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP) show sustained reductions in protoporphyrin IX (PPIX), significant improvement in light tolerance measures, and favorable longer-term safety
Management will host a corporate update conference call on Monday, June 15 at 8:00 am ET

WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Fri, 12 Jun 2026 08:30:00 -0400

Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor use
Updated data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP) show sustained reductions in protoporphyrin IX (PPIX), significant improvement in light tolerance measures, and favorable longer-term safety
Management will host a corporate update conference call on Monday, June 15 at 8:00 am ET

WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Fri, 12 Jun 2026 08:30:00 -0400

Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor use
Updated data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP) show sustained reductions in protoporphyrin IX (PPIX), significant improvement in light tolerance measures, and favorable longer-term safety
Management will host a corporate update conference call on Monday, June 15 at 8:00 am ET

WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Fri, 12 Jun 2026 08:30:00 -0400

Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor use
Updated data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP) show sustained reductions in protoporphyrin IX (PPIX), significant improvement in light tolerance measures, and favorable longer-term safety
Management will host a corporate update conference call on Monday, June 15 at 8:00 am ET

WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical

Disc Medicine receives FDA clarity on bitopertin approval path

Tue, 09 Jun 2026 08:30:28 -0400

Disc Medicine Inc. (NASDAQ:IRON) announced it completed a Type A meeting with the FDA to discuss the Complete Response Letter for bitopertin in erythropoietic protoporphyria. The company said it aligned with the FDA that its ongoing Phase 3 APOLLO study, if successful, can serve as the basis for responding to the Complete Response Letter and could potentially support a traditional approval.

The APOLLO study is a double-blind, placebo-controlled Phase 3 trial of bitopertin in patients ages 12 and above with erythropoietic protoporphyria and X-linked protoporphyria. The study includes sites in the US, Canada, Europe, and Australia.

Data from APOLLO is expected in

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

Tue, 09 Jun 2026 08:30:00 -0400

Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approval
On track for expected CRL response submission by end of 2026

WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it has completed a Type A meeting with the US Food and Drug Administration (FDA) to discuss the Complete Response Letter

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

Tue, 09 Jun 2026 08:30:00 -0400

Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approval
On track for expected CRL response submission by end of 2026

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

Tue, 09 Jun 2026 08:30:00 -0400

Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approval
On track for expected CRL response submission by end of 2026

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

Tue, 09 Jun 2026 08:30:00 -0400

Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approval
On track for expected CRL response submission by end of 2026

Disc Medicine (IRON) Reiterated at Buy by Stifel

Wed, 03 Jun 2026 06:56:48 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $111.00 price target on Disc Medicine (NASDAQ: IRON).

The analyst commented, "P2 RALLY-MF data (DISC-0974 in MFrelated anemia) were featured as an oral presentation at today’s ASCO meeting. Results are largely-unsurprising/consistent and remain impressive – with DISC-0974 continuing to demonstrate compelling efficacy agnostic to baseline anemia severity and concomitant JAKi therapy. Additional RALLY-MF data is anticipated in 4Q26 and management expects to have an end-of-P2 meeting with FDA by YE26. Given the P2 RALLY-MF trial is targeting ~30 patients/cohort and today’s update now includes >30 efficacy-evaluable non-TD patients, we expect the YE26

Disc Medicine reports positive anemia trial results at ASCO meeting

Tue, 02 Jun 2026 08:00:18 -0400

Disc Medicine Inc. (NASDAQ: IRON) presented updated data from its RALLY-MF Phase 2 trial of DISC-0974 for myelofibrosis-associated anemia at the American Society of Clinical Oncology Annual Meeting in Chicago.

The trial enrolled 61 adult patients with myelofibrosis and anemia, with 50 patients having sufficient follow-up for analysis. Patients were divided into three groups: non-transfusion dependent (31 patients), transfusion dependent with low burden (11 patients), and transfusion dependent with high burden (8 patients).

Results showed 55% of non-transfusion dependent patients achieved a hemoglobin increase of at least 1.5 g/dL for 12 weeks or longer. Among transfusion dependent patients with low burden, 64%

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Tue, 02 Jun 2026 08:00:00 -0400

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status
Anemia response was seen independent of concomitant JAK inhibitor therapy use

WATERTOWN, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presents updated data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASCO Annual Meeting in Chicago, IL. In this updated data set, treatment with DISC-0974 shows substantial reductions in

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Tue, 02 Jun 2026 08:00:00 -0400

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status
Anemia response was seen independent of concomitant JAK inhibitor therapy use

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Tue, 02 Jun 2026 08:00:00 -0400

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status
Anemia response was seen independent of concomitant JAK inhibitor therapy use

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Tue, 02 Jun 2026 08:00:00 -0400

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status
Anemia response was seen independent of concomitant JAK inhibitor therapy use

Disc Medicine launches expanded access program for bitopertin

Mon, 01 Jun 2026 08:30:38 -0400

Disc Medicine Inc. (NASDAQ: IRON) announced the launch of an expanded access program for bitopertin, an investigational treatment for patients with erythropoietic protoporphyria and X-linked protoporphyria in the United States.

The program provides access to bitopertin for eligible patients ages 12 and above who lack satisfactory therapeutic alternatives and meet additional eligibility criteria. The expanded access program is available while bitopertin undergoes evaluation in the Phase 3 APOLLO clinical trial.

Bitopertin is an oral glycine transporter 1 inhibitor designed to modulate heme biosynthesis. The company expects topline data from the APOLLO study in the fourth quarter of 2026, followed by submission of

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Mon, 01 Jun 2026 08:30:00 -0400

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision
Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026

WATERTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the launch of an expanded access program (EAP) for bitopertin for eligible

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Mon, 01 Jun 2026 08:30:00 -0400

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision
Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Mon, 01 Jun 2026 08:30:00 -0400

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision
Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Mon, 01 Jun 2026 08:30:00 -0400

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision
Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026